In PNH, Crovalimab Maintains Long-Term Fatigue Improvements

The World Congress of Nephrology held a presentation in 2026 in Yokohama, Japan, for phase 3 COMMODORE 1 and 2 clinical trials that showed stable improvement in fatigue levels reported by individuals with paroxysmal nocturnal hemoglobinuria (PNH). In this participant observed both trials where fatigue level remained stable from week 25 to week 97 in the general population, which can be described as a common symptom of PNH that can negatively affect the quality of life.

According to Towards Healthcare, the Japan paroxysmal nocturnal hemoglobinuria treatment market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 296.41million in 2026 to approximately USD 495.7 million by 2035, representing a compound annual growth rate (CAGR) of 5.88% from 2026 to 2035. Growth is driven by a favorable healthcare infrastructure that helps Japan with a highly advanced healthcare system and a rapid adoption rate for innovative biologics, and well-structured reimbursement policies ensure patient access to expensive, rare-disease therapeutics. Japan's Pharmaceuticals and Medical Devices Agency (PMDA) also offers accelerated approval pathways for orphan drugs, which encourage pharmaceutical companies to introduce breakthrough PNH treatments to the Japanese market quickly.

About Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F)

This helps to evaluate whether patient-reported fatigue scores remain stable over time, closely approaching general population averages, which have a range of 0 to 52 points. A 5-point increase is considered clinically meaningful. The average score in the general population ranges from 43.5 to 46.6.

The COMMODORE 1 trial (NCT04432584) enrolled 44 patients who continued on crovalimab treatment with arm A and 40 patients who crossed over from eculizumab with arm B after week 25. Average FACIT-F scores range from 40.8 to 42.9 in arm A and 38.2 to 40.8 in arm B, remaining slightly below the population average.

In the COMMODORE 2 trial,129 patients were assigned to 129 patients in arm A and 68 to arm B. By week 25, the average fatigue score in arm A was similar to that of the general population. During follow-up, mean fatigue scores ranged from 41.9 to 44.3 in arm A and 40.3 to 42.2 in arm B.

A recent report by Towards Healthcare highlights that the Japan paroxysmal nocturnal hemoglobinuria treatment market is witnessing growth due to patients experiencing persistent anemia, thrombosis, and fatigue due to residual or C3-mediated conditions, with the next-generation drug. Japan has been a focal point for the approval of novel therapies. As of now, drugs like iptacopan and danicopan (Voydeya) have gained significant traction to address complement-mediated extravascular hemolysis, offering oral alternatives that improve patient quality of life.